Seeking Clues to Alnylam (ALNY) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics

Core Viewpoint - Analysts forecast a quarterly loss of $0.56 per share for Alnylam Pharmaceuticals, indicating a significant year-over-year decline of 250%, while revenues are expected to increase by 19% to $588.18 million [1]. Earnings Estimates - The consensus EPS estimate has been revised downward by 4.6% in the past 30 days, reflecting a reassessment by covering analysts [2]. - Revisions to earnings projections are crucial for predicting investor behavior and are linked to short-term stock price performance [3]. Revenue Projections - Analysts estimate 'Revenues- Product revenues, net' at $464.60 million, representing a year-over-year increase of 27.2% [5]. - 'Revenues- Royalty revenue' is projected to reach $30.71 million, indicating a substantial year-over-year increase of 189.1% [5]. - 'Revenues- Net revenues from research collaborators' are expected to be $93.37 million, showing a decline of 21.2% year-over-year [5]. Product Revenue Estimates - 'Net Product Revenues- Oxlumo' is estimated at $44.67 million, reflecting a 4.7% increase from the prior year [6]. - 'Net Product Revenues- Givlaari' is projected to be $67.46 million, indicating a 16.2% increase from the previous year [6]. - 'Net Product Revenues- Amvuttra' is expected to reach $300.02 million, showing a significant year-over-year increase of 53.7% [6]. - 'Net Product Revenues- Onpattro' is estimated at $51.23 million, indicating a year-over-year decline of 26% [7]. Stock Performance - Alnylam shares have decreased by 5.6% over the past month, contrasting with the Zacks S&P 500 composite's decline of 0.8% [7].